These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19626404)

  • 1. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease.
    Omae K; Ogawa T; Nitta K
    Heart Vessels; 2009 Jul; 24(4):301-7. PubMed ID: 19626404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
    Moore KH; Clemmer JS
    Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
    Omae K; Ogawa T; Nitta K
    Heart Vessels; 2010 May; 25(3):203-8. PubMed ID: 20512447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channels blockers and progression of kidney disease.
    Ziakka S; Kaperonis N; Ferentinou E; Karakasis F; Ntatsis G; Kourvelou C; Papagalanis N
    Ren Fail; 2007; 29(8):1003-12. PubMed ID: 18067048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-type Ca channel blockers in patients with chronic kidney disease in clinical practice.
    Abe M; Okada K; Soma M
    Curr Hypertens Rev; 2013 Aug; 9(3):202-9. PubMed ID: 24479749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension.
    Tomino Y
    Curr Hypertens Rev; 2013 May; 9(2):108-14. PubMed ID: 23971692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
    Ruggenenti P; Perna A; Benini R; Remuzzi G
    J Am Soc Nephrol; 1998 Nov; 9(11):2096-101. PubMed ID: 9808096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to an L/N-type calcium channel blocker shows renoprotective effects in patients with chronic kidney disease: the Kyoto Cilnidipine Study.
    Hatta T; Takeda K; Shiotsu Y; Sugishita C; Adachi T; Kimura T; Sonomura K; Kusaba T; Kishimioto N; Narumiya H; Tanda S; Tamagaki K; Yamada K; Kameyama H; Kido H; Harada S; Bito Y; Moriguchi J; Morimoto S; Okigaki M; Itoh H; Mori Y; Nakata T; Maki K; Sasaki S; Sawada K; Matsubara H
    J Int Med Res; 2012; 40(4):1417-28. PubMed ID: 22971493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis.
    Thamcharoen N; Susantitaphong P; Wongrakpanich S; Chongsathidkiet P; Tantrachoti P; Pitukweerakul S; Avihingsanon Y; Praditpornsilpa K; Jaber BL; Eiam-Ong S
    Hypertens Res; 2015 Dec; 38(12):847-55. PubMed ID: 26134125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Koide H; Ueda Y; Takeuchi M; Yamagishi S
    Clin Cardiol; 2011 Jun; 34(6):372-7. PubMed ID: 21432860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of T-type calcium channel blockers on renal function and aldosterone in patients with hypertension: a systematic review and meta-analysis.
    Li X; Yang MS
    PLoS One; 2014; 9(10):e109834. PubMed ID: 25330103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers?
    Kloke HJ; Branten AJ; Huysmans FT; Wetzels JF
    Kidney Int; 1998 Jun; 53(6):1559-73. PubMed ID: 9607186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
    Yamada H; Suga N; Maeda K; Kimura Y; Miura N; Futenma A; Imai H
    Arzneimittelforschung; 2010; 60(2):64-70. PubMed ID: 20329653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal effects of antihypertensive agents in parenchymal renal disease and renovascular hypertension.
    Mimran A
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S45-50. PubMed ID: 1382165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of calcium channel blockers and renin-angiotensin-aldosterone system inhibitors on changes in the estimated glomerular filtration rate in patients with polycystic kidney disease.
    Mitobe M; Yoshida T; Sugiura H; Shiohira S; Shimada K; Nitta K; Tsuchiya K
    Clin Exp Nephrol; 2010 Dec; 14(6):573-7. PubMed ID: 20700620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The comparative characteristics of the renal protective properties of angiotensin-converting enzyme inhibitors and calcium channel blockers].
    Kolesnyk MO; Lapchyns'ka II; Hromova AIe; Kassyr KhI
    Lik Sprava; 2000; (3-4):11-5. PubMed ID: 10921249
    [No Abstract]   [Full Text] [Related]  

  • 20. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
    Jain AK; Cuerden MS; McLeod I; Hemmelgarn B; Akbari A; Tonelli M; Quinn RR; Oliver MJ; Garg AX
    Kidney Int; 2012 Jun; 81(12):1248-53. PubMed ID: 22437415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.